Product Description
Clostridium botulinum type A
Mechanisms of Action: AChR Blocker
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Huons
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Korea
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Muscle Spasticity|Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HU-014 | P3 |
Completed |
Muscle Spasticity|Stroke |
2023-01-03 |